Notably, merging T-cell therapy with drugs targeting the PD-1 immune cell has shown impressive effectiveness in treating leukemia, resulting in enhanced cytolytic activities, the memory of CD8+ T cells, and IFN-γ production (183). Here, IFNG is linked to leukemia.